Macquarie Group Ltd. reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 10.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,685,032 shares of the company’s stock after selling 641,319 shares during the period. Johnson & Johnson comprises approximately 1.3% of Macquarie Group Ltd.’s portfolio, making the stock its 8th largest position. Macquarie Group Ltd.’s holdings in Johnson & Johnson were worth $739,113,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. lifted its position in Johnson & Johnson by 2.6% in the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after acquiring an additional 4,332,612 shares during the last quarter. Janus Henderson Group PLC lifted its position in Johnson & Johnson by 717.9% in the second quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock valued at $495,837,000 after acquiring an additional 3,289,763 shares during the last quarter. Vanguard Group Inc. lifted its position in Johnson & Johnson by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after acquiring an additional 3,023,110 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in Johnson & Johnson by 47.9% in the second quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock valued at $1,054,433,000 after acquiring an additional 2,581,562 shares during the last quarter. Finally, Harbour Capital Advisors LLC lifted its position in Johnson & Johnson by 13,327.8% in the second quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock valued at $18,909,000 after acquiring an additional 2,482,843 shares during the last quarter. 65.53% of the stock is owned by institutional investors and hedge funds.
Johnson & Johnson (NYSE:JNJ) opened at $133.15 on Friday. Johnson & Johnson has a one year low of $118.05 and a one year high of $148.32. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. The stock has a market cap of $357,710.00, a PE ratio of 341.41, a PEG ratio of 2.20 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. The business had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. During the same period in the previous year, the business posted $1.58 earnings per share. The business’s revenue was up 11.5% compared to the same quarter last year. research analysts predict that Johnson & Johnson will post 8.11 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.52%. Johnson & Johnson’s dividend payout ratio (DPR) is 861.54%.
A number of equities research analysts recently weighed in on JNJ shares. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price target for the company in a research report on Thursday, January 11th. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Citigroup boosted their price target on shares of Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Monday, October 23rd. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. Finally, Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the company a “hold” rating in a report on Monday, January 22nd. Four research analysts have rated the stock with a sell rating, eight have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $146.16.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://ledgergazette.com/2018/02/18/macquarie-group-ltd-sells-641319-shares-of-johnson-johnson-jnj.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.